Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Bioatla Inc (BCAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BCAB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -54.37% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 21.63M USD | Price to earnings Ratio - | 1Y Target Price 8.33 |
Price to earnings Ratio - | 1Y Target Price 8.33 | ||
Volume (30-day avg) 771300 | Beta 1.18 | 52 Weeks Range 0.24 - 4.02 | Updated Date 04/1/2025 |
52 Weeks Range 0.24 - 4.02 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.44 |
Earnings Date
Report Date 2025-03-24 | When Before Market | Estimate -0.38 | Actual -0.3 |
Profitability
Profit Margin - | Operating Margin (TTM) -102.46% |
Management Effectiveness
Return on Assets (TTM) -50.47% | Return on Equity (TTM) -139.06% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -28058011 | Price to Sales(TTM) 1.97 |
Enterprise Value -28058011 | Price to Sales(TTM) 1.97 | ||
Enterprise Value to Revenue 2.25 | Enterprise Value to EBITDA 0.31 | Shares Outstanding 58024700 | Shares Floating 34927259 |
Shares Outstanding 58024700 | Shares Floating 34927259 | ||
Percent Insiders 9.65 | Percent Institutions 52.33 |
Analyst Ratings
Rating 4 | Target Price 9 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bioatla Inc
Company Overview
History and Background
Bioatla Inc., founded in 2007, is a global biotechnology company focused on developing Conditionally Active Biologics (CABs) antibody therapeutics for cancer treatment. They focus on areas where traditional antibody approaches have limitations.
Core Business Areas
- CAB (Conditionally Active Biologics) Platform: Bioatla's core technology platform for developing antibody therapeutics that are activated in the tumor microenvironment, minimizing off-target effects.
- Therapeutic Development: Developing and commercializing CAB-based antibody therapeutics for various cancer types.
Leadership and Structure
Bioatla is led by a management team with experience in biotechnology and oncology. The organizational structure involves research and development, clinical operations, and commercial planning divisions.
Top Products and Market Share
Key Offerings
- BA3011: CAB-AXL-ADC targeting AXL-expressing tumors. Currently in clinical trials. Market share is not yet applicable as it is in development. Competitors include companies developing similar ADC technologies and AXL-targeted therapies. These include Exelixis (EXEL) and Bristol Myers Squibb (BMY).
- BA3021: CAB-ROR2-ADC targeting ROR2-expressing tumors. Currently in clinical trials. Market share is not yet applicable as it is in development. Competitors include companies developing similar ADC technologies and ROR2-targeted therapies such as Takeda (TAK).
Market Dynamics
Industry Overview
The oncology therapeutics market is a large and rapidly growing market driven by increasing cancer incidence and advancements in treatment technologies, particularly antibody therapeutics and ADCs.
Positioning
Bioatla is positioned as an innovator in the antibody therapeutics space with its CAB platform, offering potential advantages in terms of safety and efficacy. Their competitive advantage lies in this platform.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. Bioatla is positioned to capture a share of this market with its pipeline of CAB-based therapeutics. The size of the TAM is dependent on the successful development and commercialization of their therapeutic candidates.
Upturn SWOT Analysis
Strengths
- Proprietary CAB platform technology
- Potential for improved safety and efficacy compared to traditional antibodies
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on successful clinical trial outcomes
- High risk associated with drug development
- No currently marketed products
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of CAB platform to new targets and indications
- Positive clinical trial results leading to regulatory approvals
- Growing demand for targeted cancer therapies
Threats
- Competition from established pharmaceutical companies
- Failure of clinical trials
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- BMY
- TAK
- EXEL
- MRTX
Competitive Landscape
Bioatla has a novel CAB platform, which differentiates it. However, it competes with larger, more established companies with greater resources and marketed products.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily driven by research and development progress and securing funding through partnerships or equity offerings.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals of its CAB-based therapeutics.
Recent Initiatives: Recent initiatives include advancing clinical trials for BA3011 and BA3021 and exploring new applications of the CAB platform.
Summary
Bioatla has a promising conditionally active biologics platform technology and a pipeline of early-stage clinical candidates. Its greatest strength is the potential for increased safety and efficacy in tumor targeting. It is reliant on successful clinical trials and faces competition from larger pharmaceutical companies. The company should look out for clinical trial risks and regulatory hurdles.
Similar Companies
- BMY
- TAK
- EXEL
- MRTX
Sources and Disclaimers
Data Sources:
- Bioatla Inc. Website
- SEC Filings
- Industry Reports
Disclaimers:
The analysis provided is for informational purposes only and should not be considered investment advice. The data presented may not be exhaustive and is subject to change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bioatla Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-12-16 | Co-Founder, CEO & Chairman Dr. Jay M. Short Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 65 | Website https://www.bioatla.com |
Full time employees 65 | Website https://www.bioatla.com | ||
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.